BIOTECH AND PHARMANEWS

Unparalleled PFS Improvement in Relapsed Plenty of Myeloma

Bibliometric Details: Issue No: 5 | Issue Month:May | Issue Year:2022

Progression-free survival (PFS) in relapsed diverse myeloma nearly doubled with the addition of the CD38 inhibitor isatuximab (Sarclisa) to a normal proteasome inhibitor (PI) regimen, according to long-term alter to-up from a randomized trial.

Median PFS improved from 19.2 months with carfilzomib (Kyprolis) and dexamethasone (Kd) to an unparalleled 35.7 months with the addition of isatuximab (I-Kd). 2d progression-free survival (PFS2) approached 4 years, reflecting durability of medication enact.

Related Articles
  • Reimagining the Step 1 Examination Dedicated Leer Length

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage This day in 2007. Apply

Disclosures

The IKEMA trial used to be supported by Sanofi.

Moreau disclosed relationships with AbbVie, Amgen, Celgene, Janssen, Oncopeptides, Roche, and Sanofi.

Elated disclosed relationships with Janssen, Amgen, Sanofi, Celgene/Bristol Myers Squibb, Takeda, GlaxoSmithKline, Oncopeptides, Pfizer, Roche, and Adaptive.

Content Protection by DMCA.com

Back to top button